NJ Judge Invalidates Patent For Janssen Cancer Drug Zytiga
A New Jersey federal judge has invalidated a patent covering Janssen Biotech Inc.'s blockbuster oncology medication Zytiga, but said a host of generic-drug makers would have infringed that patent with their...To view the full article, register now.
Already a subscriber? Click here to view full article